Dr. Wei Lai – Hepatology & Viral Hepatitis at Ruijin Hospital Shanghai | CMCS

About Dr. Wei Lai (魏来)

Dr. Wei Lai (魏来) is a Chief Physician and Professor in the Department of Infectious Diseases and Hepatology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of China's most prestigious academic medical centers and a national leader in hepatology and infectious diseases. One of China's most distinguished hepatologists, Dr. Wei is internationally recognized for his expertise in viral hepatitis B and C, liver cirrhosis management, and the prevention and early detection of hepatocellular carcinoma (HCC) in patients with chronic liver disease. His research has made significant contributions to the understanding of hepatitis B virus (HBV) pathogenesis, antiviral therapy optimization, and the molecular mechanisms linking chronic viral hepatitis to liver cancer.

Dr. Wei leads a high-volume clinical practice within one of China's busiest hepatology departments, managing complex cases of chronic hepatitis B, hepatitis C, liver cirrhosis, and liver failure referred from across China and internationally. His practice integrates the latest antiviral therapies, non-invasive liver fibrosis assessment, and evidence-based HCC surveillance protocols to deliver comprehensive, individualized hepatological care. For international patients — particularly those from regions with high HBV prevalence, including Southeast Asia, East Asia, and sub-Saharan Africa — Dr. Wei offers access to world-class hepatology expertise at one of China's most respected academic hospitals, supported end-to-end by CMCS Shanghai's medical concierge services.

Academic Distinction & Leadership

• Chief Physician & Professor, Department of Infectious Diseases and Hepatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
• Member, Chinese Society of Hepatology — Viral Hepatitis Group
• Member, Chinese Society of Infectious Diseases
• Member, Asian Pacific Association for the Study of the Liver (APASL)
• Member, European Association for the Study of the Liver (EASL) — International
• Contributor to Chinese national guidelines for chronic hepatitis B and hepatitis C management
• Reviewer, Journal of Hepatology, Hepatology, and related international publications
• Author of peer-reviewed publications in viral hepatitis, liver fibrosis, and HCC prevention

Specializations & Expertise

Chronic Hepatitis B (CHB)

• CHB diagnosis — HBV serology (HBsAg, HBeAg, anti-HBe, anti-HBs, anti-HBc), HBV DNA quantification, HBV genotyping
• Treatment indication assessment — ALT levels, HBV DNA, liver fibrosis stage, HBeAg status, family history of HCC
• First-line antiviral therapy — tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), entecavir
• Pegylated interferon alfa therapy — patient selection, response prediction (HBsAg kinetics), and management
• HBsAg loss (functional cure) strategies — combination therapy, novel agents in clinical trials
• Drug resistance management — genotypic resistance testing and rescue therapy
• HBV reactivation — prevention and management in patients receiving immunosuppressive therapy or chemotherapy
• Hepatitis B in pregnancy — antiviral prophylaxis to prevent mother-to-child transmission, postpartum management
• HBV-related cirrhosis — antiviral therapy, portal hypertension management, HCC surveillance
• HBV-related HCC prevention — antiviral therapy to reduce HCC risk, surveillance protocols

Chronic Hepatitis C (CHC)

• CHC diagnosis — anti-HCV antibody, HCV RNA quantification, HCV genotyping (genotypes 1–6)
• Direct-acting antiviral (DAA) therapy — pan-genotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) and genotype-specific regimens
• Sustained virological response (SVR) achievement — cure rates >95% with current DAA regimens
• DAA therapy in special populations — cirrhosis, renal impairment, HIV co-infection, prior DAA failure
• Post-SVR management — liver fibrosis regression monitoring, HCC surveillance in patients with advanced fibrosis/cirrhosis
• HCV-related cirrhosis — antiviral therapy, portal hypertension management, HCC surveillance

Liver Cirrhosis & Portal Hypertension

• Cirrhosis staging — Child-Pugh score, MELD score, non-invasive fibrosis assessment (FibroScan/transient elastography, FIB-4, APRI)
• Portal hypertension management — non-selective beta-blockers (propranolol, carvedilol), endoscopic variceal ligation (EVL) coordination, TIPS evaluation
• Esophageal and gastric varices — primary and secondary prophylaxis, acute variceal bleeding management
• Ascites — diuretic therapy, large-volume paracentesis, albumin infusion, TIPS referral
• Hepatic encephalopathy — lactulose, rifaximin, dietary management
• Spontaneous bacterial peritonitis (SBP) — diagnosis, antibiotic therapy, secondary prophylaxis
• Hepatorenal syndrome — diagnosis and management
• Liver transplantation evaluation and referral for end-stage liver disease

Hepatocellular Carcinoma (HCC) Surveillance & Prevention

• HCC risk stratification in chronic HBV and HCV patients — PAGE-B score, REACH-B score, aMAP score
• HCC surveillance protocols — ultrasound ± AFP every 6 months for high-risk patients
• AFP, AFP-L3, and PIVKA-II (DCP) tumor marker monitoring
• Early HCC detection — coordination with hepatobiliary surgery and interventional radiology for curative treatment
• Antiviral therapy to reduce HCC risk in CHB and post-SVR CHC patients

Autoimmune Liver Diseases

• Autoimmune hepatitis (AIH) — diagnosis (IgG, ANA, anti-SMA, anti-LKM1), immunosuppressive therapy (prednisolone, azathioprine)
• Primary biliary cholangitis (PBC) — diagnosis (AMA, AMA-M2), ursodeoxycholic acid (UDCA) therapy, obeticholic acid for UDCA non-responders
• Primary sclerosing cholangitis (PSC) — diagnosis, management, and liver transplantation evaluation
• Overlap syndromes — AIH-PBC, AIH-PSC

Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

• NAFLD/MASLD diagnosis — ultrasound, FibroScan (CAP for steatosis, LSM for fibrosis), MRI-PDFF
• NASH/MASH — lifestyle modification, metabolic risk factor management (diabetes, hypertension, dyslipidemia)
• Advanced fibrosis in NAFLD — non-invasive assessment and monitoring
• Emerging pharmacotherapy for NASH — clinical trial access

Drug-Induced Liver Injury (DILI)

• DILI diagnosis — RUCAM causality assessment, exclusion of alternative diagnoses
• Management — drug withdrawal, supportive care, corticosteroids for immune-mediated DILI
• Immune checkpoint inhibitor-related hepatitis — diagnosis and immunosuppressive management

Clinical Excellence

• Hepatitis B Authority: Dr. Wei's primary clinical focus is chronic hepatitis B — the most common cause of liver cirrhosis and HCC in China and across Asia. His expertise encompasses the full spectrum of CHB management, from treatment indication assessment and antiviral therapy selection to the management of HBV-related cirrhosis and HCC prevention. His research into HBsAg loss (functional cure) strategies and novel antiviral agents positions him at the forefront of the rapidly evolving field of HBV cure research.
• Hepatitis C Cure Expert: With the advent of direct-acting antiviral (DAA) therapy, hepatitis C is now curable in over 95% of patients. Dr. Wei has extensive experience in DAA therapy across all HCV genotypes and in special populations — including patients with cirrhosis, renal impairment, and prior DAA failure — ensuring that every patient with hepatitis C achieves the cure they deserve.
• Liver Cirrhosis & Portal Hypertension Management: Comprehensive expertise in the management of cirrhosis complications — including variceal bleeding, ascites, hepatic encephalopathy, and spontaneous bacterial peritonitis — with a focus on preventing decompensation and preserving liver function for as long as possible.
• HCC Prevention & Surveillance: A recognized expert in HCC risk stratification and surveillance in patients with chronic liver disease. Dr. Wei's approach integrates validated risk scores, optimized surveillance protocols, and antiviral therapy to minimize HCC risk and detect early-stage tumors when curative treatment is still possible.
• International Patient Experience: Extensive experience managing international patients with chronic hepatitis B from Southeast Asia, East Asia, and sub-Saharan Africa — regions where HBV prevalence is high and access to subspecialty hepatology expertise may be limited.

Research & Academic Contributions

Dr. Wei Lai is an active clinician-researcher with publications in leading Chinese and international hepatology journals including Journal of Hepatology, Hepatology, Gut, and Alimentary Pharmacology & Therapeutics. His research interests include:

• Chronic hepatitis B — HBsAg loss strategies, novel antiviral agents, and HCC risk reduction
• HBV pathogenesis — cccDNA biology, HBV integration, and immune evasion mechanisms
• Liver fibrosis — non-invasive assessment, regression with antiviral therapy, and biomarker development
• HCC prevention in chronic liver disease — risk stratification, surveillance optimization, and antiviral therapy impact
• Direct-acting antiviral therapy for hepatitis C — real-world outcomes and special populations
• NAFLD/NASH — non-invasive diagnosis and emerging pharmacotherapy

Hospital Affiliation

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (上海交通大学医学院附属瑞金医院)
197 Ruijin Er Road, Huangpu District, Shanghai 200025

Ruijin Hospital's Department of Infectious Diseases and Hepatology is one of China's most respected hepatology centers, offering:

• Dedicated viral hepatitis clinic with high-volume CHB and CHC management
• Non-invasive liver fibrosis assessment: FibroScan (transient elastography with CAP), MRI-PDFF, serum fibrosis markers
• Comprehensive HBV and HCV virology laboratory: HBV DNA, HCV RNA, HBV genotyping, HCV genotyping, resistance testing
• HCC surveillance program with ultrasound, AFP, AFP-L3, and PIVKA-II monitoring
• Liver biopsy service for cases requiring histological assessment
• Multidisciplinary liver disease team with hepatobiliary surgery, interventional radiology, and oncology
• Clinical trial access — investigational therapies for HBV cure and NASH
• International patient services with English-speaking coordinators

Patient Care Philosophy

• Cure When Possible: For hepatitis C, cure is achievable in over 95% of patients with current DAA therapy. For hepatitis B, functional cure (HBsAg loss) is the ultimate goal, and Dr. Wei pursues this target through optimized antiviral therapy and, where appropriate, participation in clinical trials of novel HBV cure agents.
• Prevention Over Treatment: The best outcome for a patient with chronic hepatitis B or C is to prevent cirrhosis and HCC from ever developing. Dr. Wei's approach prioritizes early antiviral therapy initiation, rigorous HCC surveillance, and lifestyle modification to minimize the long-term consequences of chronic liver disease.
• Non-Invasive Assessment: Liver biopsy is no longer routinely required for most hepatology decisions. Dr. Wei integrates FibroScan, serum fibrosis markers, and advanced imaging to assess liver fibrosis non-invasively — avoiding unnecessary invasive procedures while maintaining diagnostic accuracy.
• Long-Term Relationship: Chronic liver disease requires lifelong management. Dr. Wei supports long-term follow-up planning, including remote consultation coordination for international patients between visits to Shanghai.

Why Choose Dr. Wei Lai?

• Hepatitis B Subspecialty Expertise: Focused expertise in chronic hepatitis B — the most common cause of liver cancer in Asia — with particular knowledge of HBsAg loss strategies, HBV-related cirrhosis management, and HCC prevention.
• Hepatitis C Cure: Expert management of hepatitis C with current DAA therapy, including complex cases with cirrhosis, renal impairment, and prior treatment failure.
• HCC Prevention Focus: Rigorous HCC risk stratification and surveillance — ensuring early detection when curative treatment is still possible.
• World-Class Institution: Ruijin Hospital is one of China's most prestigious academic medical centers, with advanced non-invasive liver assessment, comprehensive virology laboratory, and a multidisciplinary liver disease team.
• International Patient Friendly: Experienced with international patients from HBV-endemic regions and supported by CMCS's end-to-end concierge services.
• Cost-Effective Excellence: World-class hepatology care in Shanghai at a fraction of the cost of equivalent centers in the US, UK, or Australia.

International Patient Services

China Medical Concierge - Shanghai (CMCS) provides comprehensive support for international patients seeking hepatology consultation with Dr. Wei Lai at Ruijin Hospital.

Pre-Consultation Support

• Medical Record Review: Review of all available liver function tests, HBV/HCV serology and viral load results, liver imaging (ultrasound, CT, MRI, FibroScan), liver biopsy reports, and prior hepatology treatment records before your appointment
• Virtual Pre-Consultation: Video consultation to discuss your liver condition and determine the most appropriate diagnostic and treatment pathway
• Appointment Coordination: Direct booking with Dr. Wei Lai's clinic at Ruijin Hospital
• Visa Assistance: Medical visa invitation letters and guidance
• Accommodation: Hotel recommendations near Ruijin Hospital in Huangpu District, Shanghai

During Your Visit

• Professional Medical Interpretation: Experienced English-Chinese medical interpreters for all consultations and investigations
• Hospital Navigation: Assistance with registration, payment, and coordination of same-day investigations
• 24/7 Emergency Support: Round-the-clock assistance throughout your stay in Shanghai

Post-Consultation Care

• Medical Report Translation: Complete translation of consultation notes, laboratory reports, imaging results, and FibroScan reports
• Follow-Up Coordination: Coordination of follow-up appointments, antiviral therapy monitoring, and HCC surveillance scheduling
• Telemedicine Follow-Up: Virtual consultations for ongoing liver disease monitoring and antiviral therapy management after returning home
• Home Physician Liaison: Communication of findings and treatment plan to your home country hepatologist or GP

Treatment Protocols & Patient Journey

Step 1: Pre-Consultation Review

CMCS Shanghai coordinates a review of all available liver investigations — liver function tests (ALT, AST, GGT, ALP, bilirubin, albumin, INR), HBV serology (HBsAg, HBeAg, anti-HBe, anti-HBs, HBV DNA), HCV serology (anti-HCV, HCV RNA, HCV genotype), liver imaging (ultrasound, CT, MRI, FibroScan), tumor markers (AFP, AFP-L3, PIVKA-II), and prior treatment records — before your first appointment with Dr. Wei.

Step 2: In-Person Consultation & Clinical Assessment

Your consultation begins with a thorough clinical history and abdominal examination. Dr. Wei will review all available investigations in detail and may recommend same-day investigations — including FibroScan for non-invasive liver fibrosis assessment, liver ultrasound, or additional blood tests — where indicated. CMCS provides full medical interpretation throughout.

Step 3: Diagnostic Workup (Where Indicated)

Depending on your condition, additional investigations may be recommended, including FibroScan (transient elastography with CAP for steatosis assessment), HBV genotyping and resistance testing, HCV genotyping, liver MRI with hepatobiliary contrast for lesion characterization, liver biopsy for cases where non-invasive assessment is inconclusive, or upper GI endoscopy for variceal screening in cirrhotic patients. CMCS coordinates all bookings and accompanies you through each investigation.

Step 4: Treatment Planning & Initiation

Following review of all clinical and investigative findings, Dr. Wei will provide a clear diagnosis and structured treatment plan. For CHB patients, this includes antiviral therapy selection (TAF, TDF, or entecavir), treatment monitoring schedule, and HCC surveillance protocol. For CHC patients, DAA therapy is selected based on HCV genotype, fibrosis stage, and prior treatment history, with a target of SVR (cure) within 8–12 weeks. CMCS coordinates prescription fulfillment and provides guidance on medication management.

Step 5: Antiviral Therapy Monitoring

Antiviral therapy monitoring — including liver function tests, HBV DNA or HCV RNA, and HCC surveillance — is coordinated by CMCS in collaboration with Dr. Wei's team. For CHB patients on long-term antiviral therapy, monitoring visits are scheduled at 3–6 month intervals. For CHC patients on DAA therapy, SVR assessment (HCV RNA at 12 weeks post-treatment) is coordinated remotely. CMCS liaises with your home country hepatologist or GP to ensure monitoring is performed locally where possible.

Step 6: Long-Term Follow-Up & HCC Surveillance

Long-term follow-up for patients with chronic liver disease includes regular HCC surveillance (ultrasound ± AFP every 6 months), liver fibrosis monitoring (annual FibroScan or serum markers), and antiviral therapy optimization. CMCS coordinates remote follow-up consultations with Dr. Wei for international patients between visits to Shanghai, and liaises with your home country hepatologist to ensure continuity of care.

Frequently Asked Questions

I have chronic hepatitis B. Do I need antiviral treatment?

Not all patients with chronic hepatitis B require immediate antiviral therapy. Treatment is indicated when there is evidence of active viral replication (elevated HBV DNA), liver inflammation (elevated ALT), significant liver fibrosis (assessed by FibroScan or biopsy), or a high risk of HCC (family history, cirrhosis, older age). Dr. Wei will assess your individual HBV profile — HBV DNA level, HBeAg status, ALT, fibrosis stage, and HCC risk factors — to determine whether antiviral therapy is indicated and which agent is most appropriate. For patients not yet requiring treatment, a structured monitoring plan will be established.

Is hepatitis C curable? What treatment is available in China?

Yes. Hepatitis C is now curable in over 95% of patients with current direct-acting antiviral (DAA) therapy. China has approved pan-genotypic DAA regimens including sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret), as well as genotype-specific regimens. Treatment duration is typically 8–12 weeks. DAA therapy is available at Ruijin Hospital and is significantly less expensive in China than in Western countries. Dr. Wei will select the most appropriate regimen based on your HCV genotype, fibrosis stage, and prior treatment history.

I have liver cirrhosis from hepatitis B. What can be done?

Liver cirrhosis from hepatitis B can be stabilized and, in some cases, partially reversed with effective antiviral therapy. Dr. Wei's approach to HBV-related cirrhosis includes: (1) antiviral therapy to suppress HBV replication and halt further liver damage; (2) management of portal hypertension complications (varices, ascites, encephalopathy); (3) rigorous HCC surveillance every 6 months; and (4) evaluation for liver transplantation in patients with decompensated cirrhosis. CMCS can coordinate all aspects of cirrhosis management at Ruijin Hospital.

How often should I be screened for liver cancer if I have chronic hepatitis B?

International guidelines (AASLD, EASL, APASL) recommend HCC surveillance with liver ultrasound every 6 months for all patients with cirrhosis and for high-risk non-cirrhotic CHB patients (men over 40, women over 50, family history of HCC, or high HBV DNA). AFP measurement is recommended alongside ultrasound in Asian guidelines. Dr. Wei will assess your individual HCC risk using validated risk scores (PAGE-B, REACH-B, aMAP) and establish a personalized surveillance protocol. CMCS can coordinate surveillance imaging at Ruijin Hospital during your visits to Shanghai.

What languages does Dr. Wei's team communicate in?

Dr. Wei's clinical team communicates primarily in Mandarin Chinese. CMCS Shanghai provides full English medical interpretation for all consultations and investigations.

Schedule Your Consultation

If you or a family member is seeking expert hepatology evaluation, chronic hepatitis B or C management, liver cirrhosis care, or HCC surveillance and prevention in Shanghai, CMCS Shanghai can arrange a consultation with Dr. Wei Lai at Ruijin Hospital.

• 📧 Email: contract@medicalsh.com
• 💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
• 🌐 Website: www.medicalsh.com

CMCS Shanghai — Connecting international patients with China's top hepatologists, from first inquiry to full recovery.

Disclaimer: This profile is intended for educational and informational purposes only. CMCS Shanghai is a medical concierge service and does not provide direct medical care. All clinical decisions are made by licensed physicians at accredited hospitals.